NEW YORK (GenomeWeb) – China's BGI said this week that it has received a CLIA certificate of registration for its Hong Kong laboratory.

BGI said the certification will help it to expand its offering of clinical sequencing services for specific diseases, including cancer and Mendelian disorders. It will also be useful for genomics-based clinical trial testing as part of BGI's CRO pharma solutions, which support drug discovery and development for biopharmaceutical clients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.